Feb 14, 2020: Pharma major Lupin Limited announced the launch of Moxifloxacin Ophthalmic Solution USP, 0.5%, having received an approval from the U.S. FDA earlier. The product would be manufactured at the Lupin’s Pithampur (Unit-II) facility in India. Moxifloxacin Ophthalmic Solution USP, 0.5% is the AT2-rated generic equivalent of the Moxeza® of Novartis.
It is indicated for the treatment of bacterial conjunctivitis which is caused by susceptible strains of certain organisms. Moxifloxacin Ophthalmic Solution USP, 0.5% (RLD: Moxeza®) had an annual sales of about USD 10 million in the U.S. (IQVIA MAT December 2019).
Lupin has 15 production facilities, seven research centres, more than 20,000 global employees, and has been widely known as a ‘ great place to work ‘ in the biotechnology & pharmaceuticals industry.
http://www.lupinpharmaceuticals.com/lupin-launches-moxifloxacin-ophthalmic-solution-usp-0-5.htm
